Search research articles
Contact Us
Filters
Showing results (81-90 of 353) with videos related to
Page
of 36
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology
|
October 16, 2002
Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model
Zhongmin Zhou, Marc S Penn, Farhad Forudi, et al.
The Annals of Thoracic Surgery
|
August 28, 2007
Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies
Cornelius M Dyke, Gabriel Aldea, Andreas Koster, et al.
The American Journal of Cardiology
|
June 15, 2007
Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis)
C Michael Gibson, Yuli Ten, Sabina A Murphy, et al.
European Heart Journal
|
June 19, 2007
Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach
Eugenia Nikolsky, Roxana Mehran, George Dangas, et al.
The American Journal of Cardiology
|
August 15, 2022
Longitudinal High-Sensitivity C-Reactive Protein and Longer-Term Cardiovascular Outcomes in Optimally-Treated Patients With High-Risk Vascular Disease
Iryna Dykun, Donald Clark, Julie Carlo, et al.
JACC. Case Reports
|
July 4, 2025
Coronary Stent Infection in Acute Double Valve Endocarditis
Filip Stembal, Maria Bakaeen, Valentina Lara Erazo, et al.
The Lancet. Diabetes & Endocrinology
|
December 7, 2023
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
Kausik K Ray, Stephen J Nicholls, Na Li, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
December 31, 2005
Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis
Ramin Ebrahimi, A Michael Lincoff, John A Bittl, et al.
American Heart Journal
|
June 1, 2002
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)
A Michael Lincoff, Neal S Kleiman, Kandace Kottke-Marchant, et al.
The American Journal of Cardiology
|
March 23, 2021
Prediabetic Patient Outcomes 8 to 15 Years After Drug-Eluting Coronary Stenting
Stephen G Ellis, Leslie Cho, Russell Raymond, et al.
Page
of 36
Search research articles
Search
Showing results (81-90 of 353) with videos related to
Sort By:
Page
of 36
Arteriosclerosis, Thrombosis, and Vascular Biology
|
October 16, 2002
Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model
Zhongmin Zhou, Marc S Penn, Farhad Forudi, et al.
The Annals of Thoracic Surgery
|
August 28, 2007
Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies
Cornelius M Dyke, Gabriel Aldea, Andreas Koster, et al.
The American Journal of Cardiology
|
June 15, 2007
Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis)
C Michael Gibson, Yuli Ten, Sabina A Murphy, et al.
European Heart Journal
|
June 19, 2007
Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach
Eugenia Nikolsky, Roxana Mehran, George Dangas, et al.
The American Journal of Cardiology
|
August 15, 2022
Longitudinal High-Sensitivity C-Reactive Protein and Longer-Term Cardiovascular Outcomes in Optimally-Treated Patients With High-Risk Vascular Disease
Iryna Dykun, Donald Clark, Julie Carlo, et al.
JACC. Case Reports
|
July 4, 2025
Coronary Stent Infection in Acute Double Valve Endocarditis
Filip Stembal, Maria Bakaeen, Valentina Lara Erazo, et al.
The Lancet. Diabetes & Endocrinology
|
December 7, 2023
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
Kausik K Ray, Stephen J Nicholls, Na Li, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
December 31, 2005
Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis
Ramin Ebrahimi, A Michael Lincoff, John A Bittl, et al.
American Heart Journal
|
June 1, 2002
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)
A Michael Lincoff, Neal S Kleiman, Kandace Kottke-Marchant, et al.
The American Journal of Cardiology
|
March 23, 2021
Prediabetic Patient Outcomes 8 to 15 Years After Drug-Eluting Coronary Stenting
Stephen G Ellis, Leslie Cho, Russell Raymond, et al.
Page
of 36